Pituitary Macroadenoma Diagnosis and Management

Definition and Classification

Pituitary adenomas are neoplasms arising from the hormone-secreting cells of the anterior pituitary, with macroadenomas being ≥1 cm in diameter 1
Macroadenomas can cause symptoms through mass effect on surrounding structures and/or hormonal dysfunction, as defined by the Endocrine Society 1, 2

Cranial nerve palsies, particularly oculomotor nerve dysfunction, can occur in large tumors due to mass effect 2
Raised intracranial pressure can occur in severe cases of macroadenoma 2
Prolactin excess can occur in prolactinomas, a type of macroadenoma 3
TSH excess can cause hyperthyroidism in thyrotropinomas, a type of macroadenoma 4

MRI with high-resolution pituitary protocols is the gold standard imaging modality for diagnosing macroadenomas, as recommended by the American College of Radiology 5
Contrast enhancement increases the conspicuity of adenomas, which typically appear as hypoenhancing lesions 5
Visual field testing is mandatory for macroadenomas that approach or compress the optic chiasm, according to the American Academy of Ophthalmology 5

Indications for surgery in prolactinomas include visual field defects that don't improve with medical therapy, as stated by the Endocrine Society 3
Surgery may be considered for patients with growing tumors when other treatment modalities have failed, as recommended by the American Association of Neurological Surgeons 3

Regular MRI surveillance is necessary to monitor for tumor growth or recurrence, as recommended by the National Comprehensive Cancer Network 4
Hormonal evaluation should be performed periodically to assess pituitary function, according to the Endocrine Society 4
Visual field testing should be repeated if there are concerns about tumor growth affecting vision, as stated by the American Academy of Neurology 6

About 70% of pituitary adenomas are associated with hormonal hypersecretion syndromes, and stereotactic radiosurgery (SRS) offers effective tumor control in the majority of patients with hormone-producing pituitary adenomas, according to the Journal of Neurosurgery 7
SRS has shown crude tumor control rates of 97.0% for acromegaly, 92.0% for Cushing's disease, and 93.0% for prolactinomas, as reported in the Journal of Neurosurgery 7

Visual acuity impairment requires early formal assessment including visual fields and fundoscopy, according to the Endocrine Society 8
Pituitary apoplexy (acute hemorrhage or infarction) presents with sudden severe headache, visual loss, and altered consciousness, as reported by the Endocrine Society 8, 9

Hypopituitarism occurs in 34-89% of patients with macroadenomas and manifests through deficiency of one or multiple pituitary hormones, including hypogonadism, hypothyroidism, hypocortisolemia, and growth hormone deficiency, as stated by the Endocrine Society 8, 9
Central diabetes insipidus (arginine vasopressin deficiency) is extremely rare at initial presentation of a macroadenoma unless apoplexy has occurred, according to the Endocrine Society 9, 10
The triad of headache, visual impairment, and hypogonadism represents the most common presenting constellation in surgical series, as reported by the Endocrine Society 8